BioPharmSignal logoBioPharmSignal

Biotech News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics (FATE)Fate TherapeuticsCompany update

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune

Related news

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

FATEFate Therapeutics2026-06-04 12:30 EST

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-07-31 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-22 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-06-01 21:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

View all latest news

Fate Therapeutics

iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells. FT819 FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific...

Recent company news

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Stock data

Close
2.49 USD
Market cap
299.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States